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Instrument-assisted Soft Tissue Mobilization: Eff ects on the Properties of Human Plantar Flexors
tion following eccentric exercise may be important components for the recovery of muscle tissue [ 20 ] . Though this research provides the most recent mechanistic example of the response to soft tissue mobilization in an animal model, the physiological diff erences to that of human subjects may limit its clinical applicability [ 11 , 35 ] . In contrast, the research fi ndings on IASTM often describe clinical markers such as range of motion (ROM) and functional measures, but are not derived from randomized controlled studies [ 15 ] . Collectively, however, it appears that soft tissue mobilization therapies may play a role in reducing infl ammation [ 6 ] . The purpose of this project was to evaluate the eff ects of IASTM on intramuscular infl ammation, pain, ROM and strength following muscle damage in a randomized controlled laboratory experiment.
Introduction

▼
According to the marketing information for Graston Technique ® , a form of instrument-assisted soft tissue mobilization (IASTM), more than 16 000 clinicians currently employ this technique for treating soft tissue ailments [ 17 ] . This does not include the number of clinicians and alternative medicine providers utilizing other forms of IASTM techniques such as sound-assisted soft tissue mobilization (SASTM), ASTYM ® , GuaSha, or others. Interestingly, the ability of IASTM to ameliorate loss of function, pain and infl ammation has yet to be clarifi ed. There are several physiological hypotheses as to how soft tissue mobilization works. These include increased blood fl ow, increased lymphatic drainage of toxins, reduced tissue stiff ness, alteration in neuromuscular activity and a decreased infl ammatory response [ 48 ] . However, the current literature fails to support these claims. Recently, studies have evaluated the eff ects of soft tissue mobilization on the recovery of muscular attributes following eccentric exercise-induced muscle damage [ 13 , 14 ] . Interestingly, it has been demonstrated that the intensity of the compressive load and the timing of applica-
The eff ect of instrument-assisted soft tissue mobilization (ISTM) on passive properties and infl ammation in human skeletal muscle has not been evaluated. Passive properties of muscle, infl ammatory myokines and subjective reporting of functional ability were used to identify the eff ects of ISTM on the plantar fl exors. 11 healthy men were measured for passive musculotendinous stiff ness (MTS), passive range of motion (PROM), passive resistive torque (PASTQ) and maximum voluntary contraction peak torque (MVCPT) for plantar fl exor muscles of the lower leg. Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were measured from muscle biopsies from the gastrocnemius, and subjective measurements of functional ability were taken using the perception of functional ability questionnaire (PFAQ). MTS, PROM, PRT and MVCPT were measured in the treatment leg (TL) and control leg (CL) before, immediately after, 24 h, 48 h and 72 h following IASTM. Biopsies for IL-6 and TNF-α and PFAQ responses were collected before as well as 24 h, 48 h and 72 h after IASTM. There were no signifi cant diff erences in MTS, PROM, PASTQ, MVCPT, IL-6 and TNF-α between the TL or CL. A signifi cant decrease in the perception of function and a signifi cant increase in pain for the TL were found following IASTM.
for current or ongoing neuromuscular diseases, musculoskeletal injuries, or skin disorders specifi c to the plantar fl exors. Participants reported that they had neither recently taken nor were currently using non-steroidal anti-infl ammatory drugs (NSAID), aspirin, or other anti-thrombotic over-the-counter or prescription medications. Participants were instructed not to participate in exercise 24 h prior to their fi rst scheduled visit to the laboratory or throughout the 4 subsequent days during data collection. This study was approved by the University Institutional Review Board for Human Subjects, and all participants completed a written informed consent form and a Health & Exercise Status Questionnaire. This study also meets the ethical standards established by the International Journal of Sports Medicine [ 21 ] .
Research design
A repeated measures design was used to examine the acute eff ects of the IASTM on plantar fl exors musculotendinous stiffness (MTS), passive range of motion (PROM), and maximal voluntary contraction peak torque (MVPT), perception of functional ability questionnaire (PFAQ) responses, and intramuscular levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) myokines. The participants visited the laboratory 5 times. The fi rst day included familiarization with the protocol, screening of inclusion and exclusion criteria and signing the informed consent. The second visit was within 7 days of the initial visit and was the fi rst of 4 corresponding days of data collection. The fi rst day of data collection included random assignment of the IASTM treatment leg (TL), muscle biopsy 1 (MB1) from the control leg (CL), pre-IASTM isokinetic assessment of the TL and CL, the IASTM treatment protocol to the TL and the post-IASTM isokinetic assessment of the TL and CL. The post-IASTM assessments occurred immediately after the treatment. The subsequent 3 visits included muscle biopsy of the TL only and isokinetic assessment of the TL and CL. All experimental trials were performed at the same time of day ( ± 15 min).
MTS
Musculotendinous stiff ness of the plantar fl exors was quantifi ed. MTS is the ability of the combined musculotendinous unit to prevent a change in length when force is applied [ 37 ] . This was measured using a fourth-order polynomial regression model that was fi tted to the passive angle-torque curves for each subject [ 32 ] . The fourth-order polynomial model was chosen over other models (i. e., second-order polynomial and StenKnudson) based on the comparative recommendation of Nordez [ 32 ] and because the fourth-order polynomial is classically used in the literature to assess in vivo MTS [ 28 , 29 , 40 ] . MTS quantifi es the joint angle-specifi c stiff ness of the musculotendinous unit based on the passive angle-torque relationship. MTS was calculated for each 1 ° increment in the passive angle-torque relationships from the neutral ankle position of 0 ° (i. e., 90 ° between the foot and leg) to the end of the range of motion. The ROM for each measure was determined using the position signal from the isokinetic dynamometer. The fi nal MTS value that was calculated for the joint angles commonly achieved during both the pre-and post-treatment trials was analyzed. For example, if MTS values were obtained for a subject at 10 °, 11 ° and 12 ° during the pretreatment assessment, and MTS values were calculated at 10 °, 11 °, 12 ° and 13 ° for the post-treatment assessment, then the values at 12 ° were used for analysis, because this joint angle was common to both the pre-and post-treatment assessments. MTS values were calculated using the following equation [ 32 ] , where θ represented the joint angle, and m , n , o , p , and q were coefficients in the fourth-order polynomial regression model that was fi t to the passive angle-torque relationship:
MTS was subsequently calculated with the following equation [ 32 ] .
PROM
The passive range of motion (PROM) of the plantar fl exors was determined for each participant during the pre-and post-treatment assessments using the isokinetic dynamometer programmed in passive mode. PROM is the measure of the terminal end of motion in a joint facilitated by passively moving the limb. This is typically determined by the patient's subjective indication of when the limbs movement becomes painful [ 22 ] . Maximum PROM was determined for each individual during the trial as the point of discomfort, but not pain, as verbally acknowledged by the subject during a passive stretch of the plantar fl exors while the leg was in terminal knee extension. The dynamometer lever arm passively dorsifl exed the foot at an angular velocity of 5 °/s until the end range of motion. PROM was calculated as the range of motion attained from 0 ° (neutral) to the maximum tolerable point of passive dorsifl exion. No gravity correction was performed based on the methods of Muir [ 30 ] , who indicated that the foot constituted approximately 1.4 % of the body's mass [ 50 ] and suggested that this mass can be considered negligible.
MVPT
To determine maximal voluntary contraction peak torque (MVPT), each participant performed two 5-s isometric MVCs of the plantar fl exors at a neutral ankle joint angle (0 ° = 90 ° between the foot and leg), while the knee joint was in terminal knee extension. The MVPT is the force produced at a specifi c angle in a patient's range of motion. A 2-min rest was allowed between trials. The MVPT for each trial was determined as the highest consecutive 0.25 s epoch. The same 0.25 s epoch were selected for the EMG signals to calculate the time domain estimates during the MVC trials. The mean PT value from the 2 MVC trials was used as the representative score for further analyses. The participants were instructed to give a maximum eff ort for each trial and strong verbal encouragement was provided by the investigators.
Surface EMG
EMG was collected to ensure all PROM assessments were passive according to Gajdosik et al. (2005) . Pre-amplifi ed bipolar, active surface EMG electrodes were placed on the medial gastrocnemius (MG) and soleus (SOL) muscles. The electrode confi guration (TSD150B, Biopac Systems Inc.; Santa Barbara, California, USA) had a fi xed center-to-center interelectrode distance of 20 mm, built-in diff erential amplifi er with a gain of 350 (nominal), input impedance of 100 MΩ, and common mode rejection ratio of 95 dB (nominal). For the SOL, the electrodes were placed along the longitudinal axis of the tibia at 66 % of the distance between the medial condyle of the femur and the medial malleolus. The electrodes for the MG were placed on the most prominent bulge of the muscle per the recommendations of [specify author] [ 23 ] . A single pre-gelled, disposable electrode (Ag-Ag Cl, Quinton Quick Prep, Quinton Instruments Co., Bothell, Washington, USA) was placed on the spinous process of the seventh cervical vertebrae to serve as a reference electrode. To reduce interelectrode impedance and increase the signal-to-noise ratio, local areas of the skin were shaved, lightly abraded, and cleaned with isopropyl alcohol prior to placement of the electrodes.
Signal processing
The EMG and torque signals were recorded simultaneously with a Biopac data acquisition system (MP150WSW, Biopac Systems, Inc. Santa Barbara, California, USA) during each MVPT and PROM assessment. The for torque (Nm), signals from the dynamometer and EMG (μV) signals were sampled at 2 kHz and recorded from the SOL and MG. All signals were stored on a personal computer (Dell Inspiron 8200, Dell, Inc., Round Rock, Texas, USA), and processing was completed off -line using custom written software (LabVIEW v 7.1, National Instruments, Austin, Texas, USA). The EMG signals were digitally fi ltered (zero-phase fourth-order Butterworth fi lter) with a pass band of 10-500. The torque signal was low-pass fi ltered with a 10 Hz cutoff (zero-phase fourthorder Butterworth fi lter). All subsequent analyses were performed on the fi ltered signals.
PFAQ
The Perception of Functional Ability Questionnaire (PFAQ) was developed by panel of physicians, athletic trainers and patients. 6 critical domains were identifi ed for the assessment of functional ability during a functional task: physical health, fl exibility, muscular strength, pain, restriction of sport, skill and activity of daily living (ADL) performance. To assess the 6 domains, an 8-question questionnaire with associated visual analogue scale from 0-10 was developed. The PFAQ was evaluated for testretest reliability using 60 college-aged students following procedures described by Levine [ 25 ] . Internal consistency was assessed for all items collectively using Chronbach's alpha ( = 0.856), with a score of 0.8 being considered good and 0.9 excellent. Each participant completed the PFAQ prior to the muscle biopsy and isokinetic testing on each of the testing days.
IASTM protocol
The IASTM protocol was administered by a certifi ed athletic trainer who with over 13 years of experience and who had com- Table 1 . a b Fig. 1 a , b IASTM with level and ELF System attached to ensure consistent pressure and angles. 
Muscle biopsy
Following collection of ROM, PT and SL1-RM measures, percutaneous muscle biopsies (~100 mg) [ 1 ] were taken from the gastrocnemius of each subject of the TL and CL on days 4 and 5. All biopsies were obtained from the mid-belly region of the muscle, and each biopsy was 2-3 cm proximal from the previous site and within the region treated by IASTM. Each subject received standard antiseptic application to each biopsy site followed by an injection of 3 cc of local anesthetic (2 % lidocaine) to each biopsy site. The subject then rested for 5 min to ensure that the area was suffi ciently anesthetized. An incision approximately 0.5 cm wide and 1 cm deep was then made using a scalpel (#11 Blade) approximately 6-8 cm from the joint line of the knee. All samples were then placed in liquid nitrogen and stored at − 80 °C until analysis.
Muscle processing
Approximately 20 mg of each muscle sample was homogenized in extraction buff er (Biosource; Carlsbad, CA) using a glass-onglass tissue grinder. Homogenized samples were centrifuged at 4 °C at 3 000 rpm for 4 min. For determining total protein, supernatant was separated from the pellet and the sample was diluted (1:1 000) in preparation for analysis using a bicinchoninic acid (BCA) protein assay (Pierce; Rockford, IL). All samples were measured in triplicate using a Synergy microplate reader (BioTek, Winooski, VT) at 450 nm.
Western blotting
Muscle samples were diluted with 5x buff er (IL-6) or 1x buff er (TNF-α) and heated for 3 min at 100 °C. 80 μg of protein was loaded for each sample and placed on a 5 % stacking and 10 % separating gel at 0.05 mA for 1 h. Proteins were transferred to hydrophobic polyvinylidene difl uoride (PVDF) membranes at 0.20 mA for 2 h. Membranes were blocked for 1 h in a Tris-buffered saline with 5 % nonfat dry milk on a rocker at room temperature. Membranes were then incubated at 4 °C on a plate rocker overnight in a 1:1 000 IL-6 (Cell Signaling Technology, Inc., Beverly, MA) or TNF-α antibody (Cell Signaling Technology, Inc., Beverly, MA) which was normalized to tubulin (Cell Signaling Technology, Inc., Beverly, MA) in TBST and 1 % nonfat dry milk solution. Following the overnight incubation, membranes were rinsed 3 times for 5 min in TBST. Membranes were incubated in horseradish peroxidase conjugated secondary antibody for an hour and once again rinsed 3 times for 5 min in TBST. Membranes were then incubated in chemiluminescence. IL-6 and TNF-α (Santa Cruz Biotechnology, Santa Cruz, CA) protein bands were then visualized and quantifi ed using densitometry (AlphaView ® FluorChemHD2 v.3.4.0.0, Protein Simple, Santa Clara, CA). 
Statistical analyses
Results
▼
MTS
For MTS, there were no signifi cant two-way interactions (time × treatment, P = 0.92) and no signifi cant main eff ects for time (P = 0.63) or treatment (P = 0.89) ( • ▶ Fig. 2 ).
PROM
For PROM, there were no signifi cant two-way interactions (time × treatment, P = 0.78) and no signifi cant main eff ects for time (P = 0.11) or treatment (P = 0.64) ( • ▶ Fig. 3 ). 
MVPT
For MVPT, there were no signifi cant two-way interactions (time × treatment, P = 0.25) and no signifi cant main eff ects for time (P = 0.6) or treatment (P = 0.45) ( • ▶ Fig. 4 ).
PFAQ
A signifi cant diff erence was found for time for the subjective measures of the treated body part's ability to perform activities of daily living (P = 0.02) and pain (P = 0.006). Subjective measures of the treated body part's ability to perform activities of daily living signifi cantly changed from baseline measures at 24 h (P = 0.045) and 48 h (P = 0.03) following IASTM. Subjective measures of pain signifi cantly increased from baseline measures at 24 h (P = 0.005), 48 h (P = 0.20) and 72 h (P = 0.03) following IASTM. No signifi cant diff erences were found for any of the reported measures of the PFAQ following IASTM over time Table 2 ).
IL-6
For IL-6, there were no signifi cant diff erences (P = 0.82) at any point in time following IASTM ( • ▶ Fig. 5 ).
TNF-α
For TNF-α, there were no signifi cant diff erences (P = 0.68) at any point in time following IASTM ( • ▶ Fig. 6 ).
Discussion
▼
The present study indicates that IASTM does not change the passive properties, MTS, PROM or MVPT, in healthy human skeletal muscle. To our knowledge, our data represent the only evaluation of passive muscle properties and subjective measures of function following IASTM performed on healthy human skeletal muscle. The majority of studies examining the eff ects of soft tissue mobilization on muscle strength show no benefi ts [ 3 , 43 , 51 ] . These data are contrary to previous research in an in-vivo animal model indicating that viscoelastic properties are eff ected acutely and accumulatively through massage-like loads [ 7 ] . Davidson et al. (1997) and Loghmani and Warden (2009) have also previously shown a localized healing response in injured animal models [ 9 , 26 ] . To our knowledge, no studies have examined the eff ects of IASTM on MTS. The current data also indicate that subjective measures of the treated body part's pain and ability to perform activities of daily living decreased following IATSM. This does not align with the majority of data measuring the use of IASTM in clinical pathology case studies. These data indicate a perceived decrease in pain measures and a perceived increase in functional ability [ 34 , 49 ] . Gehlsen et al. (1999) indicate that the application of heavy pressure with the instruments is needed for promoting the induction of the healing process [ 14 ] . This is contrary to the techniques currently taught during IASTM courses. Instructors encourage appropriate clinical pressure that is tolerable to the patient and that will not cause severe pain or bruising to the treatment area [ 17 ] . The current data indicate that IASTM using appropriate clinical pressure with the instrument held within the accepted treatment angle does not cause muscle damage or initiate the infl ammatory process in healthy human muscle tissue. Additionally, it indicates that this specifi c IASTM treatment did not change MTS, increase PROM or change MVPT values following treatment in healthy human muscle tissue. The physiological response to specifi c treatment pressure(s) and treatment angle(s) are currently unknown. Likewise, the diff erences in the physiological response to IASTM in healthy and injured human soft tissue are currently unknown. Manual therapy techniques, such as massage, have been studied for effi cacy in the clinical treatment of muscle [ 2 , 13 , 19 , 20 ] . Specifi cally, studies have measured how manual mobilization of soft tissue can increase function [ 12 ] , aid in recovery following exercise [ 43 ] and decrease subjective pain measures [ 19 , 20 , 39 , 43 ] . Loss of function in patients suff ering from muscle damage is commonly present alongside decreases in range of motion and strength. Changes in range of motion are often associated with the accumulation of extracellular fl uids and increased pain with movement [ 18 , 33 , 44 ] . Decreases in strength following eccentric exercise damage protocols are thought to be a response from decreased excitation-contraction coupling [ 24 ] , localized accumulation of immune and infl ammatory markers [ 42 ] and ultra-structural changes to the contractile proteins in the muscle [ 36 ] . In the case of muscle damaged from high-intensity exercise or injury, loss of function and notable increases in pain are often a result of structural changes in the tissue [ 8 , 31 ] and a localized infl ammatory response [ 27 ] , including localized infl ux of leukocytes that produce prostaglandins that sensitize type III and IV nerve endings [ 4 ] . This acute infl ammatory response is associated with increased localized blood fl ow and myokine levels, including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Our data indicate that levels of intramuscular myokines, IL-6 and TNF-α, do not increase following IASTM. These data are contradictory to previous research by Crane et al. [ 6 ] evaluating the eff ect of massage following muscle damage protocol. While previous case studies have reported successful outcomes from the application of IASTM to clinical pathologies [ 34 , 49 ] , our data does not indicate that the neuromechanical and infl ammatory properties or subjective measures of function change signifi cantly following IASTM on healthy human skeletal muscle. It should be noted that the IASTM protocol did not follow a typical clinical pattern of warming the tissue with modalities or exercise followed by evaluating the tissue with soft tissue massage or with the instruments. Following the evaluation of tissue the clinician would use multiple instruments with multiple stroke techniques in multiple directions, including cross frictional strokes. Further evaluation of the neuromechanical and infl ammatory eff ects of IASTM on human skeletal muscle is needed. Specifi cally, knowledge about how IASTM may eff ect skeletal muscle in patients suff ering from clinical pathologies would provide clinicians with data for evidence-based therapy.
Other measures used to assess function include musculotendinous stiff ness (MTS), passive range of motion (PROM) and maximal voluntary contraction peak torque (MVPT). MTS is the ability of the combined musculotendinous unit to prevent a change in length when force is applied [ 37 ] . PROM is the measure of the terminal end of motion in a joint allowed by passively moving the limb. This is typically determined by the patient's subjective indication of when the limbs movement becomes painful [ 22 ] . MVPT is the force produced at a specifi c angle in a patient's range of motion. The force-producing capability of muscle following interventions such as static stretching [ 5 ] as well as the application of ice and heat [ 16 ] has been previously examined.
Dynamic changes, such as strength, also reportedly decreased immediately following damage and lasted approximately 10 days [ 46 ] . It has been shown previously that passive muscle properties signifi cantly change following trauma. Neuromechanical properties such as muscle tendon stiff ness (MTS), maximal voluntary contraction peak torque (MVPT), and passive range of motion (PROM) all suff er following injury [ 47 ] . Damage to skeletal muscle also results in a localized infl ammatory response, an increase in localized blood fl ow and myokine levels, including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [ 27 ] . IL-6 inhibits infl ammation by stimulating the production of the anti-infl ammatory cytokines including IL-1ra, IL-10 and soluble TNF-α receptors [ 38 ] . It has been observed that the severity of symptoms, including reduction in passive range of motion (ROM), is a refl ection of muscle damage. These passive changes are related to mechanical alterations [ 22 ] . Altogether, the athlete or patient will have diminished capacities of function as well as a changed perception of his or her ability to perform functional activities. A patient's perception of functional ability is associated with his or her subjective level of musculoskeletal pain [ 45 ] . Clinically, physicians use both subjective measures and objective measures of pain, muscle strength and range of motion to determine return to activity decisions [ 10 ] . The perception of reduced functional ability is associated with strength and ROM restrictions following trauma [ 41 ] . Clinicians incorporate numerous techniques and modalities as countermeasures for injury and to mitigate pain. Manual therapy techniques, such as instrument-assisted soft tissue mobilization (IASTM), are often used to address the patient's subjective complaints and objective loss of function.
